Press Releases Clinuvel Pharmaceuticals Limited

Equities

Market Closed - Australian S.E. Other stock markets 11:40:14 09/05/2024 am IST			5-day change	1st Jan Change
14.91 ^AUD	-3.62%		-1.00%	-6.81%

29/04	Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%	MT
14/03	Clinuvel Pharmaceuticals Launches Share Buyback Program	MT

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors	28/03	AQ
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine	05/03	AQ
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care	01/23/01	AQ
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings	24/23/24	AQ
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals	02/23/02	AQ
CLINUVEL Trial Results Show Drug Reduces DNA Damage	16/23/16	AQ
Clinuvel Pharmaceuticals : Appendix 4C & Activity Report	25/22/25	PU
Clinuvel Pharmaceuticals : Change of Director’s Interest Notice	23/22/23	PU
Clinuvel Pharmaceuticals : Change of Director’s Interest Notice	14/22/14	PU
Clinuvel Pharmaceuticals : H.C. Wainwright Global Investment Conference Presentation	26/22/26	PU
Clinuvel Pharmaceuticals : H.C. Wainwright Global Investment Conference 2022	26/22/26	PU
Clinuvel Pharmaceuticals : Notice of change of interests of initial substantial holder	25/22/25	PU
Clinuvel Pharmaceuticals : Notice of initial substantial holder	20/22/20	PU
CLINUVEL progresses vitiligo treatment program	10/22/10	AQ
Positive final results in stroke	04/22/04	AQ
Letter to shareholders from CLINUVEL’s CEO	29/22/29	AQ
Clinuvel Pharmaceuticals : CEO letter	29/22/29	PU
Clinuvel Pharmaceuticals : Quarterly Activities/Appendix 4C Cash Flow Report	28/22/28	PU
Clinuvel Pharmaceuticals : Appendix 4C & Activity Report	28/22/28	PU
Clinuvel Pharmaceuticals : Notice of ceasing to be a substantial holder	27/22/27	PU

No results for this search